Last reviewed · How we verify

Adapalene-BPO Gel

Galderma Brasil Ltda. · FDA-approved active Small molecule

Adapalene-BPO is a combination topical gel that uses a retinoid (adapalene) to normalize skin cell turnover and reduce inflammation, combined with benzoyl peroxide to kill acne-causing bacteria and provide additional anti-inflammatory effects.

Adapalene-BPO is a combination topical gel that uses a retinoid (adapalene) to normalize skin cell turnover and reduce inflammation, combined with benzoyl peroxide to kill acne-causing bacteria and provide additional anti-inflammatory effects. Used for Acne vulgaris.

At a glance

Generic nameAdapalene-BPO Gel
SponsorGalderma Brasil Ltda.
Drug classRetinoid + peroxide combination
TargetRetinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)
ModalitySmall molecule
Therapeutic areaDermatology
PhaseFDA-approved

Mechanism of action

Adapalene is a third-generation retinoid that binds to retinoic acid receptors, promoting keratinocyte differentiation and reducing comedone formation. Benzoyl peroxide acts as an antimicrobial agent against Cutibacterium acnes (formerly Propionibacterium acnes) and generates reactive oxygen species that reduce bacterial colonization. Together, they address multiple pathogenic factors in acne: follicular hyperkeratinization, bacterial proliferation, and inflammation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: